| Literature DB >> 33169545 |
Jiejin Yang1, Zeyang Chen2, Weipeng Liu3, Xiangpeng Wang3, Shuai Ma1, Feifei Jin4, Xiaoying Wang5.
Abstract
OBJECTIVE: The mitotic count of gastrointestinal stromal tumors (GIST) is closely associated with the risk of planting and metastasis. The purpose of this study was to develop a predictive model for the mitotic index of local primary GIST, based on deep learning algorithm.Entities:
Keywords: Deep learning Multidetector computed tomography; Gastrointestinal stromal tumors; Mitotic index
Mesh:
Substances:
Year: 2020 PMID: 33169545 PMCID: PMC7909867 DOI: 10.3348/kjr.2019.0851
Source DB: PubMed Journal: Korean J Radiol ISSN: 1229-6929 Impact factor: 3.500
Fig. 1Flow diagram of the study patients.
*Sixteen patients were excluded for the following reasons: 10 patients had incomplete imaging data, two patients received neoadjuvant therapy before surgery, and four patients had missing pathological mitotic counts. †Low mitotic count (≤ 5/50 HPFs), ‡High mitotic count (> 5/50 HPFs). GIST = gastrointestinal stromal tumors, HPFs = high-power fields
Fig. 2A 72-year-old man with primary GIST.
Postoperative pathology showed a mitotic count of 8/50 HPFs. (A–C) showed the original axial CT image, segmented image, and pre-processed image of the tumor respectively. We used image labeling software to segment the tumor area in the CT image as the region of interest, which is the blue area in (B). Next, image preprocessing was performed on the basis of image segmentation and got the preprocessed image (C). The developed model predicted the image mitotic index classification and output the corresponding class activation heatmap (D).
Fig. 3VGG16 neural network architecture.
Clinical Characteristics of Patients in Different Cohorts
| Mitotic Index | Training Cohort (n = 108) | Validation Cohort (n = 20) | Test Cohort (n = 20) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ≤ 5/50 HFPs | > 5/50 HFPs | P | ≤ 5/50 HFPs | > 5/50 HFPs | P | ≤ 5/50 HFPs | > 5/50 HFPs | P | |
| Gender | 0.700 | 0.350 | 1.000 | ||||||
| Male | 28 | 25 | 8 | 5 | 5 | 4 | |||
| Female | 26 | 29 | 2 | 5 | 5 | 6 | |||
| Age (years) | 60.8 ± 10.2 | 60.2 ± 11.2 | 0.768 | 63.8 ± 10.9 | 62.7 ± 12.4 | 0.835 | 58.9 ± 11.3 | 63.3 ± 11.1 | 0.392 |
| Tumor site | 0.321 | 1.000 | 1.000 | ||||||
| Gastric | 36 | 31 | 6 | 7 | 5 | 6 | |||
| Non-gastric | 18 | 23 | 4 | 3 | 5 | 4 | |||
| Tumor size (cm) | 5.4 ± 4.1 | 7.7 ± 4.7 | 0.007 | 4.5 ± 1.6 | 9.5 ± 5.6 | 0.014 | 7.2 ± 4.2 | 13.2 ± 9.8 | 0.089 |
| Risk categories | |||||||||
| None | 8 | 4 | 1 | 0 | 0 | 0 | |||
| Very low | 19 | 0 | 3 | 0 | 3 | 0 | |||
| Low | 16 | 0 | 5 | 0 | 2 | 0 | |||
| Moderate | 6 | 13 | 0 | 2 | 2 | 0 | |||
| High | 5 | 37 | 1 | 0 | 3 | 10 | |||
Data are presented as mean ± SD or n. Independent samples t test was applied in continuous variables. Chi-Squared test was applied in categorical variables. The risk stratification adopted the Armed Forces Institute of Pathology criteria (Miettinen's criteria). HPF = high-power field
The Statistical Results at the Image Level (Number of Pictures)
| Mitotic Index | Training Cohort (n = 108) | Validation Cohort (n = 20) | Test Cohort (n = 20) | |||
|---|---|---|---|---|---|---|
| ≤ 5/50 HFPs | > 5/50 HFPs | ≤ 5/50 HFPs | > 5/50 HFPs | ≤ 5/50 HFPs | > 5/50 HFPs | |
| True | 2044 | 3130 | 331 | 717 | 411 | 910 |
| False | 453 | 354 | 104 | 139 | 198 | 152 |
| Total | 2497 | 3484 | 435 | 856 | 609 | 1062 |
| Accuracy (95% CI), % | 86.5 (0.856–0.874) | 81.2 (0.790–0.833) | 79.1 (0.771–0.810) | |||
| Sensitivity (95% CI), % | 89.8 (0.888–0.908) | 83.8 (0.811–0.861) | 85.7 (0.834–0.877) | |||
| Specificity (95% CI), % | 81.9 (0.803–0.833) | 76.1 (0.717–0.800) | 67.5 (0.636–0.712) | |||
| Positive predictive value (95% CI), % | 87.4 (0.862–0.884) | 87.3 (0.848–0.895) | 82.1 (0.797–0.843) | |||
| Negative predictive value (95% CI), % | 85.2 (0.837–0.866) | 70.4 (0.660–0.744) | 73.0 (0.691–0.766) | |||
CI: confidence interval
Fig. 4ROC curves of different data set.
A. Image-level ROC. B. Patient-level ROC. ROC = region of interest
The Statistical Results at the Patient Level (Number of Patients)
| Mitotic Index | Training Cohort (n = 108) | Validation Cohort (n = 20) | Test Cohort (n = 20) | |||
|---|---|---|---|---|---|---|
| ≤ 5/50 HFPs | > 5/50 HFPs | ≤ 5/50 HFPs | > 5/50 HFPs | ≤ 5/50 HFPs | > 5/50 HFPs | |
| True | 48 | 50 | 7 | 9 | 7 | 9 |
| False | 6 | 4 | 3 | 1 | 3 | 1 |
| Total | 54 | 54 | 10 | 10 | 10 | 10 |
| Accuracy (95% CI), % | 90.7 (0.852–0.963) | 80.0 (0.608–0.992) | 80.0 (0.608–0.992) | |||
| Sensitivity (95% CI), % | 92.6 (0.813–0.976) | 90.0 (0.541–0.995) | 90.0 (0.541–0.995) | |||
| Specificity (95% CI), % | 88.9 (0.767–0.954) | 70.0 (0.354–0.919) | 70.0 (0.354–0.919) | |||
| Positive predictive value (95% CI), % | 88.9 (0.767–0.954) | 75.0 (0.428–0.933) | 75.0 (0.428–0.933) | |||
| Negative predictive value (95% CI), % | 92.3 (0.806–0.975) | 87.5 (0.467–0.993) | 87.5 (0.467–0.993) | |||
The Predicted Tumor Risk Category Results (Number of Patients)
| Mitotic Index | Training Cohort (n = 108) | Validation Cohort (n = 20) | Test Cohort (n = 20) | |||
|---|---|---|---|---|---|---|
| Low-Mitotic | High-Mitotic | Low-Mitotic | High-Mitotic | Low-Mitotic | High-Mitotic | |
| True | 50 | 50 | 7 | 9 | 8 | 10 |
| False | 4 | 4 | 3 | 1 | 2 | 0 |
| Total | 54 | 54 | 10 | 10 | 10 | 10 |
| Accuracy (95% CI), % | 92.6 (0.876–0.976) | 80.0 (0.608–0.992) | 90.0 (0.756–1.000) | |||
| Sensitivity (95% CI), % | 92.6 (0.813–0.986) | 90.0 (0.541–0.995) | 100.0 (0.656–1.000) | |||
| Specificity (95% CI), % | 92.6 (0.813–0.986) | 70.0 (0.354–0.919) | 80.0 (0.442–0.965) | |||
| Positive predictive value (95% CI), % | 92.6 (0.813–0.986) | 75.0 (0.428–0.933) | 83.3 (0.509–0.971) | |||
| Negative predictive value (95% CI), % | 92.6 (0.813–0.986) | 87.5 (0.467–0.993) | 100.0 (0.598–1.000) | |||